[Predictive markers in breast cancer treatment--focusing on a recent topic "basal-like breast cancer"].
Koike
Ayaka
A
Division of Breast and Endocrine Surgery, St. Marianna University School of Medicine.
Ohta
Tomohiko
T
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D019313:BRCA1 Protein / Q000235:genetics; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D004250:DNA Topoisomerases, Type II; D004268:DNA-Binding Proteins; D047628:Estrogen Receptor alpha; D005260:Female; D005544:Forecasting; D000077156:Gefitinib; D020869:Gene Expression Profiling; D006801:Humans; D009154:Mutation; D020411:Oligonucleotide Array Sequence Analysis; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D011980:Receptors, Progesterone; D014404:Tubulin
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D019313:BRCA1 Protein; D004250:DNA Topoisomerases, Type II; D004268:DNA-Binding Proteins; D047628:Estrogen Receptor alpha; D000077156:Gefitinib; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D011980:Receptors, Progesterone; D014404:Tubulin; C492913:BRCA1 protein, human